Table 1.
Participant characteristics.
| Variable | Patients (n = 37) | Controls (n = 14) | p |
|---|---|---|---|
| Age, y | 52±12 | 58±5 | 0.090 |
| Weight, kg | 77±20 | 68±9 | 0.131 |
| BMI, kg·m−2 | 27±5 | 25±4 | 0.211 |
| Cancer type | |||
| Ductal | 28 (76) | – | – |
| Invasive | 2 (5) | – | – |
| Lobular | 7 (19) | – | – |
| Cancer stage | – | – | |
| IA | 2 (5) | – | – |
| II/IIA/IIB | 20 (54) | – | – |
| IIIA/IIIC | 15 (41) | – | – |
| Surgery | |||
| Lumpectomy | 9 (24) | – | – |
| Mastectomy/partial mastectomy | 28 (76) | – | – |
| Time since primary diagnosis, mo.; median (IQR) | 21.7 (9.4, 43.0) | – | – |
| Time since chemotherapy, mo.; median (IQR) | 16.3 (5.8, 32.3) | – | – |
| Additional therapy | – | – | |
| Cytotoxic therapy* | 31 (84) | – | – |
| Radiation | 28 (76) | – | – |
| Endocrine therapy | 26 (70) | – | – |
| Cardiac risk factors | |||
| Hypertension | 10 (27) | 1 (7) | 0.251 |
| Hyperlipidemia | 5 (14) | 0 (0) | 0.305 |
| Diabetes | 1 (3) | 0 (0) | >0.999 |
| Current and (or) history of smoking | 3 (8) | 0 (0) | 0.552 |
| Exercise behavior | |||
| Total exercise, min·wk−1† | 184±141 | 442±315 | <0.001 |
| Moderate plus vigorous-intensity exercise, min·wk−1† | 108±109 | 359±302 | <0.001 |
| CDC/ACSM guidelines | 12 (32) | 8 (57) | 0.014 |
| Cardiorespiratory fitness | |||
| V̇O2peak, mL·kg−1·min−1 | 23.5±6.3 | 30.6±7.0 | 0.001 |
| V̇O2peak, L·min−1 | 1.7±0.4 | 2.1±0.4 | 0.015 |
Note: Data are presented as means ± SD for continuous data and n (%) for categorical data, except as noted. BMI, body mass index; IQR, interquartile range; CDC/ACSM, Centers of Disease Control/American College of Sports Medicine; V̇O2peak, peak oxygen consumption.
*
Cytotoxic therapy includes taxol, xeloda, abraxane.
†
Data available on 35 breast cancer patients and 10 controls.